Literature DB >> 26202031

Familial clustering of hepatocellular carcinoma in HBsAg-positive patients in the United States.

Myron John Tong1,2, Thatcher Thi Huynh3, Surachate Siripongsakun3,4,5.   

Abstract

PURPOSE: The impact of familial clustering of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV)-infected persons in a low HBV endemic area was investigated.
METHODS: Four hundred thirteen HBsAg-positive patients, 173 with HCC and 240 without HCC, were subgrouped into those with or without a family history of HCC and analyzed for risk factors associated with HCC development. In families with HCC clustering, the ages of HCC onset in parents and siblings were compared.
RESULTS: Forty-four of 173 (25.4 %) HCC patients, all of Asian descent, had 82 other blood relatives with HCC. Of these, 69 (84.1 %) were first-degree relatives. Compared to HCC patients without HCC family history, male HCC patients with family history developed HCC at a younger age than either their mothers or fathers with HCC (45.2 ± 10.3 years vs. 63.0 ± 6.8 years, p < 0.001 and 41.2 ± 14.8 years vs. 60.5 ± 5.5 years, p = 0.001, respectively); however, this was not observed in female HCC patients. In mothers of index HCC cases, 22/26 (84.6 %) tested were HBsAg positive and 14 (63.6 %) had HCC; in fathers, 11/21 (52.4 %) tested were HBsAg positive and 10 (90.9 %) had HCC. By multivariate analysis, independent risk factors for HCC development included family history (OR = 2.58, p = 0.05), male gender (OR = 3.23, p = 0.03), cirrhosis (OR = 2.4, p = 0.04), Child-Pugh classification (OR = 7.62, p = 0.004), AFP per log10 increase (OR = 1.68, p = 0.01), precore mutation (OR = 3.77, p = 0.003), and basal core promoter mutation (OR = 8.33, p < 0.001).
CONCLUSIONS: HBsAg-positive male HCC patients presented at a younger age than their parents with HCC. In adult patients with an HCC family history, HCC surveillance should begin at the time of the initial clinic encounter.

Entities:  

Keywords:  Familial clustering; Hepatitis B; Hepatocellular carcinoma

Year:  2013        PMID: 26202031     DOI: 10.1007/s12072-013-9447-y

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  36 in total

1.  World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective.

Authors:  Peter Ferenci; Michael Fried; Douglas Labrecque; J Bruix; M Sherman; M Omata; J Heathcote; T Piratsivuth; Mike Kew; Jesse A Otegbayo; S S Zheng; S Sarin; S Hamid; Salma Barakat Modawi; Wolfgang Fleig; Suliman Fedail; Alan Thomson; Aamir Khan; Peter Malfertheiner; George Lau; F J Carillo; Justus Krabshuis; Anton Le Mair
Journal:  J Gastrointestin Liver Dis       Date:  2010-09       Impact factor: 2.008

2.  Familial hepatoma with hepatitis-associated antigen.

Authors:  E K Denison; R L Peters; T B Reynolds
Journal:  Ann Intern Med       Date:  1971-03       Impact factor: 25.391

3.  Family history of liver cancer and hepatocellular carcinoma.

Authors:  Federica Turati; Valeria Edefonti; Renato Talamini; Monica Ferraroni; Matteo Malvezzi; Francesca Bravi; Silvia Franceschi; Maurizio Montella; Jerry Polesel; Antonella Zucchetto; Carlo La Vecchia; Eva Negri; Adriano Decarli
Journal:  Hepatology       Date:  2012-03-21       Impact factor: 17.425

4.  Fraternal hepatocellular carcinoma in young children in two families.

Authors:  M H Chang; H C Hsu; C Y Lee; D S Chen; C H Lee; K S Lin
Journal:  Cancer       Date:  1984-04-15       Impact factor: 6.860

Review 5.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

6.  Primary malignant tumor of liver in infants and children in Taiwan.

Authors:  W J Chen; J C Lee; W T Hung
Journal:  J Pediatr Surg       Date:  1988-05       Impact factor: 2.545

7.  Tumor factors associated with clinical outcomes in patients with hepatitis B virus infection and hepatocellular carcinoma.

Authors:  Myron John Tong; Surachate Siripongsakun; Gaelen Stanford-Moore; Leeyen Hsu; Patrick Weijen Chang; Lawrence Mitchell Blatt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-12

8.  Primary hepatocellular carcinoma and hepatitis B infection during childhood.

Authors:  T C Wu; M J Tong; B Hwang; S D Lee; M M Hu
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

9.  Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma.

Authors:  Chien-Hung Chen; Yang Yuan Chen; Gran-Hum Chen; Sien-Sing Yang; Huang-Shang Tang; Hsien Hong Lin; Deng-Yn Lin; Sing Kai Lo; Jeng-Ming Du; Ting-Tsung Chang; Shinn-Cherng Chen; Li-Ying Liao; Chung-Huang Kuo; Kwo-Chuan Lin; Dar-In Tai; Chi-Sin Changchien; Wen-Yu Chang; Jin-Chuan Sheu; Ding-Shinn Chen; Yun-Fan Liaw; Juei-Low Sung
Journal:  J Hepatol       Date:  2004-04       Impact factor: 25.083

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  3 in total

1.  Association of family history with long-term prognosis in patients undergoing liver resection of HBV-related hepatocellular carcinoma.

Authors:  Zhen-Li Li; Jun Han; Kai Liu; Hao Xing; Han Wu; Wan Yee Lau; Timothy M Pawlik; Chao Li; Ming-Da Wang; Jiong-Jie Yu; Meng-Chao Wu; Feng Shen; Tian Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2019-04       Impact factor: 7.293

2.  Genetic susceptibility of eight nonsynonymous polymorphisms in HLA-DRB1 gene to hepatocellular carcinoma in Han Chinese.

Authors:  Yanhui Shi; Weiyu Zhai; Bin Wang; Dongmei Zhao; He Jin; Yuefei Wang; Jidong Zhang; Hongjun An; Zhongze Fu; Kun Zhao; Changzhu Lu
Journal:  Oncotarget       Date:  2016-12-06

3.  Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis.

Authors:  Zongguo Yang; Liping Zhuang; Yunfei Lu; Qingnian Xu; Bozong Tang; Xiaorong Chen
Journal:  Oncotarget       Date:  2016-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.